AviaraDx and MGH Collaborate in Molecular Cancer Profiling Study
News May 19, 2006
AviaraDx, Inc., formerly known as Arcturus Bioscience, Inc., has announced that it has entered into a major research collaboration with the Massachusetts General Hospital (MGH) Cancer Center to identify molecular profiles of multiple types of cancer for the development of diagnostic technologies and tests in the field of cancer drug response prediction.
Over the next two years, teams at MGH and AviaraDx will conduct a broad molecular profiling program to determine genes, gene signatures and polymorphisms that correlate with response to specific therapeutic agents in a wide range of different cancers.
The initiative aims to identify and commercialize tumor biomarkers that predict which patients may respond to targeted drugs.
MGH and AviaraDx will perform gene sequencing and gene expression analysis in a large number of cancers.
The project results will not only provide information to help identify patients likely to respond to a certain cancer drug, but also provide guidance with regard to a broader range of cancer types likely responding to an established drug.
Daniel A. Haber, MD, PhD, and Jeff Settleman, PhD, of MGH have extensive experience in the identification of genetic markers associated with drug response.
Most recently, they reported the identification of a gene mutation that appears to identify those lung cancer patients who will likely respond to the cancer drug Iressa®.
Mark Erlander, Ph.D. and Xiao-Jun Ma, Ph.D., of AviaraDx have developed the company's Molecular Cancer Identification (MCID) technology, which has been licensed to clinical laboratory partners in the US and Europe.
"The MGH Cancer Center is a world leading medical research center, and we are pleased to be collaborating with them in a program that may result in the development of molecular diagnostic tests for drug response prediction in cancer," said Antonius Schuh, Ph.D., Chief Executive Officer of AviaraDx, Inc.
"Transforming the molecular basis of cancer into diagnostic technologies with proven clinical utility is the core focus for AviaraDx."
"Our molecular cancer identification (MCID) and breast cancer profiling (BCP) technologies are impressive achievements in this space."
"Our goal is the development of a rational basis for the selection of a specific drug regimen in a given patient," said Dr. Haber, who is the director of the MGH Cancer Center.
"We are hopeful that this collaboration will generate technologies of relevant molecular diagnostic tests for predicting what therapy is best suited for specific patients."
High Fruit and Veg Consumption May Reduce Breast Cancer RiskNews
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers from Harvard T.H. Chan School of Public Health.READ MORE
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Why Might Super-Tasters be at Higher Cancer Risk?News
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been tracked for about 20 years.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018